XTL Biopharmaceuticals Ltd (XTLB)

1.03
0.01 1.23
NASDAQ : Health Care
Prev Close 1.04
Open 1.02
Day Low/High 1.02 / 1.03
52 Wk Low/High 0.64 / 1.99
Volume 2.70K
Avg Volume 35.00K
Exchange NASDAQ
Shares Outstanding 13.68M
Market Cap 14.22M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

XTL Biopharmaceuticals Completes Phase 2 Trial Design For Lead Compound HCDR1 In The Treatment Of Lupus

XTL Biopharmaceuticals Completes Phase 2 Trial Design For Lead Compound HCDR1 In The Treatment Of Lupus

Company to file IND with FDA and plans to commence trial in 2016

Lupus Thought Leader Daphna Paran, MD, Named Medical Director Of XTL Biopharmaceuticals

Lupus Thought Leader Daphna Paran, MD, Named Medical Director Of XTL Biopharmaceuticals

World renowned expert in the treatment of lupus with over 60 published articles and extensive clinical trial experience

XTL Biopharmaceuticals Expands Global IP Portfolio With Issued Patent In Hungary For Lupus Drug HCDR1

XTL Biopharmaceuticals Expands Global IP Portfolio With Issued Patent In Hungary For Lupus Drug HCDR1

Fortifies patent position in Europe, where Phase 2 trial is expected to commence in 2016

XTL Biopharmaceuticals Receives European Medicines Agency's SME Status

XTL Biopharmaceuticals Receives European Medicines Agency's SME Status

SME status supports XTL's European clinical program for hCDR1 in the treatment of lupus and its upcoming Phase 2 trial

XTL Biopharmaceuticals' Lupus Drug HCDR1 Granted Patent For Pharmaceutical Composition & Manufacturing Processes

XTL Biopharmaceuticals' Lupus Drug HCDR1 Granted Patent For Pharmaceutical Composition & Manufacturing Processes

Lead asset addresses unmet need in market projected to reach $4 billion

XTL Biopharmaceuticals Joins Corporate Advisory Council Of The Lupus Foundation Of America

XTL Biopharmaceuticals Joins Corporate Advisory Council Of The Lupus Foundation Of America

Collaborating to bring an effective treatment to market for the 1.5 million Americans living with lupus

XTL Biopharmaceuticals Announces Encouraging Feedback From U.S. FDA On Its Upcoming IND Filing For Lupus Drug HCDR1

XTL Biopharmaceuticals Announces Encouraging Feedback From U.S. FDA On Its Upcoming IND Filing For Lupus Drug HCDR1

Successful outcome of FDA guidance includes BILAG as the primary efficacy endpoint, patient inclusion criteria, and patient population for safety requirements for marketing approval

XTL Biopharmaceuticals Submits Protocol To Yeda For Advanced Clinical Trial Of HCDR1 In The Treatment Of Lupus

XTL Biopharmaceuticals Submits Protocol To Yeda For Advanced Clinical Trial Of HCDR1 In The Treatment Of Lupus

hCDR1 addresses significant unmet medical need for lupus, a chronic and complex disease for which there is currently no cure

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the Health Care sector lower today.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks that pushed the Drugs industry

3 Health Care Stocks Pushing The Sector Higher

3 Health Care Stocks Pushing The Sector Higher

TheStreet highlights 3 stocks that pushed the Health Care sector

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the Health Care sector lower today.

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

TheStreet highlights 3 stocks pushing the Drugs industry lower today.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the Health Care sector lower today.

3 Health Care Stocks Moving The Sector Upward

3 Health Care Stocks Moving The Sector Upward

TheStreet highlights 3 stocks that pushed the Health Care sector